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Labor induction with misoprostol
versus dinoprostone:
A meta-analysis of seven randomized trials
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José Geraldo Lopes Ramos1
OBJECTIVE: To compare the efficacy and safety of two prostaglandin analogs,
misoprostol and dinoprostone, for labor induction of third trimester pregnancies with
fetus and cervices unfavorable to oxytocin, as reported by recently published studies.
METHODS: Seven randomized, controlled and prospective studies, comparing
intravaginally applied misoprostol (n=500) with dinoprostone (n=498) were selected
from Medline. For each variable analyzed in each of the seven studies reviewed, we
used SerSimonian and Laird’s method to evaluate the homogeneity of treatment
effects. To analyze the results of each clinical trial, the relative risk was calculated
with a 95% Confidence Interval; a “common” RR for different outcomes was also
calculated using the Mantel-Haens method, with the SAS statistical package. The
following outcomes were evaluated in our study: need for oxytocin augmentation;
need for cesarean section; meconium passage; 1- and 5-minute Apgar scores.
RESULTS: When misoprostol was used instead of dinoprostone, there was a decrease
of approximately 50% in the need to use oxytocin (RR = 0.55; 0.49-0.63). No difference
was found regarding the need to perform cesarean sections in the misoprostol group
when compared to the dinoprostone group (RR = 1.04; 0.81-1.34). There was a
slightly higher incidence of meconium passage among the group that used misoprostol
(RR = 1.39; 1.03-1.86). No significant difference in the incidence of Apgar score
smaller than 7 was observed between the misoprostol or dinoprostone group, either
at the 1st (RR = 1.36; 0.92-2.26) or at the 5th minute (RR = 1.39; 0.36-5.36).
CONCLUSIONS: For the labor induction in third trimester pregnacies, with live fetus
and unfavorable cervices, misoprostol is as effective and as safe as dinoprostone. A
50 µg dose of misoprostol may cause a higher incidence of meconium passage,
however, it doesn’t compromise the perinatal performance of the newborn. The cost
of misoprostol treatment was significantly lower than the cost of dinoprostone treatment
according to the three studies that assessed this variable.
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Indução do parto com misoprostol versus dinoprostone: uma meta-análise de
sete ensaios clínicos randomizados
OBJETIVO: Comparar a eficácia e a segurança de dois análogos das prostaglandinas,
misoprostol e dinoprostone, na indução do parto em gestações de terceiro trimestre
com feto vivo e cérvice desfavorável ao uso de ocitocina, conforme relatos recentes
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na literatura.
MÉTODOS: Foram selecionados do sistema Medline sete estudos randomizados,
controlados e prospectivos, comparando misoprostol (n = 500) com dinoprostone (n
= 498) utilizados por via vaginal. Utilizou-se o método de DerSimonian e Laird para
avaliar a homogeneidade do efeito do tratamento para cada variável analisada pelos
sete estudos. Optou-se pelo risco relativo com intervalo de confiança de 95% para
avaliar o resultado de cada ensaio clínico, calculando-se também o RR “comum”
para os diferentes desfechos pelo método de Mantel-Haenszel, utilizando-se o pacote
estatístico SAS. Os seguintes desfechos foram analizados: uso de ocitocina; índice
de cesariana; eliminação de mecônio; escore de Apgar no 1º e 5º minutos.
RESULTADOS: Houve uma diminuição significativa – aproximadamente 50% –  na
necessidade de uso de ocitocina com a aplicação do  misoprostol em relação ao
dinoprostone (RR = 0,55; 0,49-0,63). Não foi encontrada nenhuma diferença na
necessidade de cesariana entre o grupo que utilizou misoprostol (RR = 1,04; 0,81-
1,34) e o que utilizou dinoprostone. Houve uma incidência ligeiramente aumentada
de eliminação mecônio no grupo do misoprostol (RR = 1,39; 1,03-1,86) em relação
ao dinoprostone. Não foi encontrada nenhuma diferença significativa entre o grupo
que utilizou misoprostol e o grupo que utilizou dinoprostone em relação à incidência
de escores de Apgar menor do que 7, tanto no 1º minuto (RR = 1,36; 0,92-2,26),
como no 5º minuto (RR = 1,39; 0,36-5,36).
CONCLUSÕES: O misoprostol por via vaginal é tão efetivo e tão seguro quanto o
dinoprostone para a indução do parto em gestações de terceiro trimestre com feto
vivo e cérvice desfavorável ao uso de citocina. A dose de 50 µg de misoprostol pode
provocar um aumento na eliminação de mecônio, sem contudo comprometer o
desempenho perinatal dos recém nascidos. O custo do tratamento com misoprostol
foi significativamente menor nos três estudos que avaliaram este item.
UNITERMOS: Cérvix: dinoprostone; parto induzido; misoprostol, ocitocina.
Revista HCPA 1998;18 (2):170-6
Introduction
Cervical ripening is a vital phenomenon for
the success of labor induction. It is characterized
by the onset of uterine contractions that initiate
labor. Induction methods have been studied since
the 16th century, and, except for the introduction
of oxytocin and prostaglandins, there has been
very little change in these methods. Pregnant
women with small uterine cervical dilation (Bishop
score less than or equal to 5) rarely respond well
to labor induction with oxytocin. At Hospital de
Clínicas de Porto Alegre (HCPA), the two most
frequent reasons for cesarean section indication
(20.4% of all indications) are failure to induce
labor using oxytocin and presence of cervices
unfavorable to induction (1).
In recent years, many researchers have
dedicated themselves to study the development
of agents that can be used to promote cervical
ripening (2-5). Dinoprostone, an estradiol
prostaglandin analog (PgE2), the only
pharmaceutical agent for cervical ripening
approved by the Food and Drug Administration
in the United States, received this approval only
after 5 years of research, and after publication
of over 70 reports on clinical trials (6). Many
researchers have shown the advantages of using
another agent, misoprostol (PgE1), an estrone
prostaglandin analog (7-12). These studies
suggest that misoprostol is safe, very effective,
stable at room temperature, easy to store and
that it costs less than dinoprostone. On the other
hand, some authors have shown that the
incidence of tachysystole, meconium passage
and nonreactive cardiotocography is higher with
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misoprostol (13, 14).
The objective of this study is to review
published randomized clinical trials which
compare dinoprostone and misoprostol in terms
os their properties to promote cervical ripening
and labor induction. The reported benefits and
risks of using misoprostol will be evaluated
through meta-analysis.
Materials and methods
After a bibliographic search in Medline, 31
articles about the use of misoprostol pregnant
women were chosen. From these, seven were
selected, since they fulfilled the criteria of being
prospective, randomized, and controlled studies,
and of comparing the effects of intracervical
application of dinoprostone to the effects of
intravaginal application of misoprostol in third
trimester pregnancies with live fetus and
unfavorable cervices to the use of oxytocin.
For each variable analyzed in each of the
seven studies, DerSimonian and Laird’s method
(D&L method, modified Cochran method) was
employed to assess the homogeneity of
treatment effects (15, 16). Treatment effects were
not considered heterogeneous in the various
studies in terms of the variables analyzed for a
significance level of 5% (α = 0.05).
The results of each clinical trial were
evaluated using the relative risk (RR) with a 95%
confidence interval. Moreover, a “common”
relative risk (typical RR) and its 95% confidence
interval were calculated for specific outcomes
reported by all the studies, through the
MantelHaenszel method, using the SAS
statistical package (17). We chose to determine
the RR because it can estimate the magnitude
of an association between exposure (PgE1 or
PgE2) and outcome. From the variables analyzed
in our study (since they were similarly analyzed
in the seven clinical trials): need for oxytocin
augmentation; need for cesarean sections;
meconium passage; Apgar score smaller than 7
at the 1st and 5th minutes. When the relative risk
could not be calculated due to the absence of
magnitude, as in the variable Apgar score smaller
than 7 at the 5th minute (8, 10, 13), a small constant
(0.5) was added to make the calculation possible (18).
Results
Use for oxytocin
There is a reduction of approximately 50%
in the need for oxytocin augmentation when
misoprostol is used, in comparison with
dinoprostone (Figure 1). This reduction happened
in all studies, independently of the dosage of
misoprostol or dinoprostone (typical RR = 0.55;
0.49-0.63). This benefit was less evident in the
study by Fletcher et al. (7), in which relatively
higher doses of dinoprostone (3 mg) were used
(RR = 0.65; 0.20-2.07), and in the study by Wing
et al. (10), in which smaller doses of misoprostol
(25 µg) were used (RR = 0.64; 0.52-0.79).
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Figure 2.  Need for cesarean section delivery. Typical RR = 1.04; χ2 for heterogeneity = 10.00.
Relative risk (95% CI)
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Figure 3. Meconium passage. Typical RR = 1.38; χ2 for heterogeneity: 3.789.
Cesarean section
No difference was found regarding need
for cesarean section deliveries between the
misoprostol group and the dinoprostone group
(RR = 1.04; 0.81-1.34) (Figure 2). The need for
cesarean sections ranged, among the various
of meconium passage in the misoprostol group
than in the dinoprostone group (typical RR = 1.39;
1.03-1.86). This was partly due to the study by
Wing et al. (13), in which 50 µg doses of
misoprostol were administrated every 3 hours,
to a maximum of six doses (RR = 2.67; 1.20-
5.95). This negative outcome was not observed
studies, from 3.1 to 35.5% for the misoprostol
group and from 9.6% to 21.5% for the
dinoprostone group (7, 14). Such variations are
related to a more or less tolerant conduct with
respect to cesarean sections, and they do not
reflect the type of prostaglandin used.
Meconium passage
Evaluation of this outcome was possible
with only four of the seven studies analyzed
(Figure 3). There was a slightly higher prevalence
when the same authors (10) used a 25 µg dose
of misoprostol every 3 hours (RR = 1,25; 0.72-
2.18). Likewise, this negative outcome was not
observed in the studies of Chuck & Huffaker (8)
(RR = 0.82; 0.23-2.86) and Mundle et al. (11)
(RR = 1.25; 0.82-1.91), which used 50 µg doses
of misoprostol, but at 4 hour intervals.
Apgar score smaller than 7
Comparing the misoprostol group to the
dinoprostone group, there was no significant
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Figura 4.  Apgar score < 7 at the 1st minute. Typical RR = 1.36;χ2 for heterogeneity =  0.800.
Figure 5. Apgar score < 7 at the 5th minute. Typical RR = 1.39; χ2 for heterogeneity: 0.379.
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difference for newborns regarding Apgar score
smaller than 7, either at the 1st (typical RR = 1.36;
0.92-2.26) or at the 5th minute (typical RR = 1.39;
0.36-5.36) (Figures 4 and 5). As with the
meconium passage variable, the study by Wing
et al. (13), which employed a 50 µg dose of
misoprostol at 3 hour intervals, had the highest
RR for Apgar score smaller than 7 (RR = 1.94 at
the 5th minute).
Discussion
The studies reviewed here selected to
enable a comparison between two types of
prostaglandins (misoprostol and dinoprostone),
and not to compare prostaglandins with oxytocin.
Clinical trials comparing prostaglandins with
oxytocin are usually inconsistent, due to
randomizing and control difficulties. Besides
having excluded patients presenting
contraindications to vaginal delivery and to
prostaglandin use, all the authors reviewed have
excluded from their studies patients with previous
uterine scarring.
All the authors reviewed assessed
induction time using various parameters, such
as: duration in relation to changes in Bishop
score; time span from the beginning of labor
induction until the actual delivery; duration of the
1st and 2nd labor stages; length of time until the
onset of uterine contractions. This diversity of
parameters got in the way of a more precise
assessment of labor induction time, although all
studies did show that misoprostol decreases the
time interval between the start of treatment and
the start of the active stage of labor or birth. This
suggests that this misoprostol, administrated in
25 to 100 µg doses, is more powerful than
dinoprostone in 0.5 or 3.0 mg doses, at least in
relation to cervical effacement and onset of
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uterine contractions. Wing et al. (10, 13) observed
a higher incidence of tachysystole with 50 µg
doses of misoprostol in comparison to 0.5 mg
doses of dinoprostone; this was not observed with
25 µg doses of misoprostol. Buser et al. (14) did
not observe a higher incidence of tachysystole
in a group of 76 patients who received 50 µg of
dinoprostone. The difficulty to find an effective
and safe dosage also occurred in the first PgE2
studies, when the vaginal gel was made from
Prostin suppositories.
The presence or not of fetal distress is
always taken into consideration when prescribing
drugs for labor induction. In a study by Fletcher
et al. (7), 63 patients received a single 100 mg
dose of misoprostol or 3 mg of dinoprostone and
were evaluated. There were no cases of  perinatal
death in either group. In the same study, no
significant difference (9.4% for misoprostol and
13% for dinoprostone) was found in terms of
hyperstimulation, that is, association of
tachysystole and fetal bradycardia.
In a study in which Wing et al. (13)
observed a higher frequency of meconium
passage with 50 µg doses of misoprostol every
3 hours, no significant differences were registered
in terms of more accurate indicators of fetal
distress, such as Apgar score, need for
resuscitation or admission to the neonatal
intensive care unit. In another study using 25 µg
doses of misoprostol, the same authors again
found no significant difference between
misoprostol or dinoprostone in terms of fetal
distress (10). Varaklis et al. (9) registered similar
pH values for the newborns’ umbical cord venous
and arterial blood for patients both in the
misoprostol group and in the dinoprostone group,
even when using 25 µg of misoprostol (every 2
hours) in comparison with 0.5 mg of dinoprostone
(every 6 hours).
Among pregnant women who received
either 50 µg of misoprostol or 0.5 mg of
dinoprostone, Mundle and Young (11) did not
observe any significant difference in terms of
nonreactive cardiotocography, umbilical cord
blood pH smaller than 7; meconium passage; or
Apgar scores (1st and 5th minute) smaller than 7.
On the other hand, Buser et al. (14) did observe
a higher incidence of hyperstimulation in the
misoprostol group (50 µg every 3 hours),
compared to the dinoprostone group (0.5 mg
every 6 hours). In the same study, no significant
difference was found in association with incidence
of 5-minute Apgar score smaller than 6, or to
neonatal intensive care unit admission and days
spent in the intensive care unit.
The treatment cost was also assessed in
some studies. Wing et al. (13) reported a cost of
0.36 dollars for every 100 µg of misoprostol and
75 dollars for every 0.5 mg of dinoprostone; 100
µg of misoprostol yields four of the indicated 25
µg doses. Chuck and Huffaker (8) reported a cost
of 0.20 dollars for each dose of misoprostol,
compared to 65 dollars per dose of dinoprostone.
Mundle and Young (11) mentioned an average
cost of 0.22 Canadian dollars for PgE1 treatment
compared to 70 Canadian dollars for PgE2
treatment. Such estimates suggest that a 50 µg
dose of misoprostol has a cash value that is 318
to 416 times lower that of a 0.5 mg dose of
dinoprostone.
Therefore, the present analysis, which
reviewed seven randomized and controlled
studies that included 998 patients (misoprostol n
= 500; dinoprostone n = 498), leads to the
conclusion that intravaginal misoprostol is as
effective and as safe as dinoprostone for labor
induction in third trimester pregnancies with live
fetus and cervices unfavorable to oxytocin. A 50
µg dose of PgE1 administered at  3 hour intervals
is associated with a higher frequency of
meconium passage, but without compromising
the perinatal performance of the newborn. The
cost of misoprostol treatment was significantly
lower in the three studies that assessed this item.
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